PCN50 COST-EFFECTIVENESS OF DOCETAXEL PLUS CYCLOPHOSPHAMIDE VERSUS DOXORUBICIN PLUS CYCLOPHOSPHAMIDE IN THE ADJUVANT TREATMENT OF OPERABLE BREAST CANCER
May 1, 2009, 00:00 AM
10.1016/S1098-3015(10)73287-3
https://www.valueinhealthjournal.com/article/S1098-3015(10)73287-3/fulltext
Section Title :
Section Order :
711
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)73287-3&doi=10.1016/S1098-3015(10)73287-3